Loading
Liver Disease Diagnosis and Treatment / Diabetes, Cardiovascular Risks, and Lipoproteins · Journal article
Biomedicines · September 3, 2026
Reinforces what was already believed, rather than introducing something new.
This large observational cohort study stratified by menopausal status demonstrates that MASLD is associated with elevated cardiovascular risk across pre- and postmenopausal women, while associations with obesity phenotype differ by menopausal stage: general obesity predicted CVD risk in premenopausal women without MASLD, whereas central obesity was more consistently associated with risk after menopause. The authors explicitly caution that these are observational contrasts between groups differing substantially in age and should not be interpreted causally, though they may inform prevention strategies tailored to menopausal stage and MASLD status.
Nationwide retrospective cohort study, stratified by menopausal status. Korean women aged ≥40 years (848,672 premenopausal, 1,110,695 postmenopausal).. Intervention: MASLD status and obesity phenotypes (general obesity, central obesity). Compared with: Comparison across menopausal status and obesity/MASLD strata. n = 1,959,367. South Korea (nationwide cohort).
During median 12.3-year follow-up, 106,792 women (5.45%) developed CVD In premenopausal women without MASLD: general obesity associated with CVD risk (aHR 1.10, 95% CI 1.04–1.17); central obesity not significantly associated (aHR 1.06, 95% CI 0.96–1.18) In postmenopausal women without MASLD: central obesity associated with CVD risk (aHR 1.08, 95% CI 1.05–1.10)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest that obesity-related cardiovascular prevention strategies should be tailored by menopausal stage and MASLD status. However, clinicians should note the source's explicit caution that observational group comparisons differing substantially in age should not be interpreted causally, and that an inverse association for general obesity in postmenopausal MASLD women was not reproduced in sensitivity analysis using a metabolic proxy.
Large observational cohort study with substantial sample size and long follow-up confirming known associations between MASLD, obesity, and cardiovascular risk, with menopausal stratification adding nuance but not overturning established knowledge.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest that obesity-related cardiovascular prevention strategies should be tailored by menopausal stage and MASLD status. However, clinicians should note the source's explicit caution that observational group comparisons differing substantially in age should not be interpreted causally, and that an inverse association for general obesity in postmenopausal MASLD women was not reproduced in sensitivity analysis using a metabolic proxy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence increases during the menopausal transition, yet its interaction with obesity phenotypes in influencing cardiovascular disease (CVD) risk remains unclear. We examined how MASLD and obesity types are associated with CVD risk in pre- and postmenopausal women. Methods: This nationwide cohort analyzed 1,959,367 Korean women aged ≥40 years (848,672 premenopausal, 1,110,695 postmenopausal) followed for a median of 12.3 years. MASLD was defined by the fatty liver index plus ≥1 cardiometabolic risk factor and alcohol intake <20 g/day. General obesity was defined as body mass index ≥25 kg/m2 and central obesity as waist circumference ≥85 cm. Results: During follow-up, 106,792 women (5.45%) developed CVD. MASLD was associated with higher CVD risk regardless of menopausal status, though the association was numerically smaller in postmenopausal women. Among women without MASLD, general obesity was associated with risk before menopause (adjusted hazard ratio [aHR] 1.10, 95% confidence interval [CI] 1.04–1.17; central obesity, aHR 1.06, 95% CI 0.96–1.18), whereas after menopause central obesity was associated with risk (aHR 1.08, 95% CI 1.05–1.10). In postmenopausal women with MASLD, the estimate for general obesity was inverse (aHR 0.95) while central obesity remained positively associated (aHR 1.05); in an exploratory sensitivity analysis using an anthropometry-free metabolic proxy (the triglyceride–glucose index), the inverse estimate was not reproduced (aHR 1.06). Conclusions: MASLD was associated with elevated CVD risk across menopausal stages. Associations with obesity phenotype varied by menopausal status: general obesity was associated with risk in premenopausal women without MASLD, whereas after menopause the association was more consistent for central obesity. These are observational contrasts between groups that also differ substantially in age and should not be interpreted causally. They may nonetheless inform prevention tailored to menopausal stage, MASLD status, and obesity phenotype.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.